Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines

Journal of Drugs in Dermatology

Volumn 11, Issue 1, 2012, Pages 38-45

  Glogau, Richard ^a,b   Blitzer, Andrew ^c   Brandt, Fredric ^d   Kane, Michael ^e   Monheit, Gary D ^f   Waugh, Jacob M ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Head and Neck Surgical Group ^*

^c Head and Neck Surgical Group   (United States)

^d Dermatology Research Institute LLC   (United States)

^e Manhattan Eye   (United States)

^f TOTAL   (France)

^g Revance Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; RT 001; UNCLASSIFIED DRUG;

ADULT; AGED; APPLICATION SITE EDEMA; ARTICLE; BURNING SENSATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HUMAN; LATERAL CANTHAL LINE; MALE; NORMAL HUMAN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SKIN FISSURE; SKINFOLD; WRINKLE;

ADMINISTRATION, TOPICAL; ADULT; AGED; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; EYELIDS; FEMALE; FOLLOW-UP STUDIES; GELS; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SKIN AGING; TREATMENT OUTCOME;

EID: 84855361077     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Olson JJ. Balanced botox chemodenervation of the upper face: Symmetry in motion. 2007. Semin Plast Surg. 2007;21(1):47-53.
2. Kane MA. Classification of crow's feet patterns among Caucasian women: The key to individualizing treatment. Plast Reconstr Surg. 2003;112(suppl 5):33S-39S. (Pubitemid 44718483)
3. Carruthers A, Carruthers JD, Glogau RG, et al. Advances in Facial Rejuvenation: Botulinum Toxin Type A, Hyaluronic Acid Dermal Fillers, and Combination Therapies-Consensus Recommendations. Plast Reconstr Surg. 2008;121(suppl 5):5S-30S. (Pubitemid 351674120)
4. Joshua ID, Senghas A, Brandt F, Ochsner KN. The Effects of BOTOX Injections on Emotional Experience. Emotion. 2010;10(3):433-440.
5. Havas DA, Glenberg AM, Gutowski KA, et al. Cosmetic Use of Botulinum Toxin-A Affects Processing of Emotional Language. Psychol Sci. 2010;21(7):895-900.
6. Tamietto M, Castelli L, Vighetti S, et al. Unseen facial and bodily expressions trigger fast emotional reactions. Proc Natl Arcad Sci U S A. 2009;106(42):17661-17666.
7. Samson N, Fink B, Matts PJ, et al. Visible changes of female facial skin surface topography in relation to age and attractiveness perception. J Cosmet Dermatol. 2010;9(2):79-88.
8. Alam M, Barrett KC, Hodapp RM, Arndt KA. Botulinum toxin and the facial feedback hypothesis: Can looking better make you feel happier? J Am Acad Dermatol. 2008;58(6):1061-1072. (Pubitemid 351657604)
9. Rinn WE. The Neuropsychology of Facial Expression: A Review of the Neurological and Psychological Mechanisms for Producing Facial Expressions. Psychol Bull. 1984;95(1):52-77.
10. Kane MA. The functional anatomy of the lower face as it applies to rejuvenation via chemodenervation. Facial Plast Surg. 2005;21(1):55-64. (Pubitemid 40868931)
11. Keen M, Blitzer A, Aviv J, et al. Botulinum toxin A for hyperkinetic facial lines: Results of a double-blind, placebo-controlled study. Plast Reconstr Surg. 1994;94(1):94-99. (Pubitemid 24243399)
12. Blitzer A, Binder W, Aviv J, et al. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg. 1997;123(4):389-392. (Pubitemid 27180937)
13. Ellis D, Tan A. Cosmetic upper-facial rejuvenation with botulinum. J Otolaryngol. 1997;26(2):92-96. (Pubitemid 27247984)
14. Fagien, S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: Adjunctive use in facial aesthetic surgery. Plast Reconstr Surg. 1999;103(2):701-703.
15. Lowe N, Lask G, Yamauchi P, Moore D. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. J Am Acad Dermatol. 2002;47(6):834-840. (Pubitemid 35403040)
16. Lowe NJ, Ascher B, Heckmann M, et al. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg. 2005;31:257-262. (Pubitemid 43072975)
17. Guerrissi J. Intraoperative injection of botulinum toxin A into the orbicularis oculi muscle for the treatment of crow's feet. Plast Reconstr Surg. 2003;112(suppl 5):161S-163S. (Pubitemid 44718496)
18. Levy JL, Servant JJ, Jouve E. Botulinum toxin A: A 9-month clinical and 3D in vivo profilometric crow's feet wrinkle formation study. J Cosmet Laser Ther. 2004;6(1):16-20. (Pubitemid 38661143)
19. Lowe N, Ascher B, Heckmann M, et al. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg. 2005;31(3):257-262. (Pubitemid 43072975)
20. Carruthers A, Bogle M, Carruthers JD, et al. A randomized, evaluator-blinded, two-center study of the safety and effect of volume on the diffusion and efficacy of botulinum toxin type A in the treatment of lateral orbital rhytides. Dermatol Surg. 2007;33(5):567-571. (Pubitemid 46650366)
21. Ascher B, Rzany B, Grover R. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: Double-blind, placebo-controlled, dose-ranging study. Dermatol Surg. 2009;35(10):1478-1486.
22. Pena M, Alam M, Yoo S. Complications with the use of botulinum toxin type A for cosmetic applications and hyperhidrosis. Semin Cutan Med Surg. 2007;26(1):29-33. (Pubitemid 46349780)
23. Matarasso S, Matarasso A. Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg. 2001;108(1):208-214. (Pubitemid 32587045)
24. Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol. 2004;22(1):66-75. (Pubitemid 38670107)
25. Carruthers J, Fagien S, Matarasso SL, Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg. 2004;114(suppl 6):1S-22S. (Pubitemid 40354480)
26. Wolff K, Goldsmith LA, Katz SI, et al., eds. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York, NY: McGraw Hill; 2008.
27. Brandt F, O'Connell C, Cazzaniga A, et al. Efficacy and Safety Evaluation of a Novel Botulinum Toxin Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines. Derm Surg. 2010;36:2111-2118.
28. Hamilton JG. Needle phobia: A neglected diagnosis. J Fam Pract. 1995;41(2):169-175.
29. Dykes P, Marks R. An evaluation of the irritancy potential of povidone iodine solutions: Comparison of subjective and objective assessment techniques. Clin Exp Dermatol. 1992;17(4):246-249.
30. Food and Drug Administration. Guidance for Industry. Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products. US Department of Health and Human Services, Center for Drug Evaluation and Research: 1999. Available at: www.fda.gov/ohrms/dockets/98fr/990236Gd.pdf.
31. Bates B. A Guide to Physical Examination and History Taking. 6th ed. Philadelphia, PA: Lippincott; 1997.
32. Yen T, Driscoll C, Lalwani A. Significance of House-Brackmann facial nerve grading global score in the setting of differential facial nerve function. Otol Neurotol. 2003;24(1):118-122. (Pubitemid 36169377)